[Discussion] can we stop arguing about dose escalation until somebody posts a number
can we stop arguing about dose escalation until somebody posts a number. Searched first, found three threads that contradict each other, hence the post. Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a…
That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.
a lot of the confident posting here is extrapolation
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
small trial, big effect, wide error bars
That reads as a titration plan for an unapproved compound.
heart_rate_bump is right about the escalation being the variable. It explains most of the difficult reports here.
the phase 2 numbers were striking and they were also 48 weeks in a small population
wait for phase 3 before you argue about rankings